Long-Term Follow-Up Affirms Ivosidenib's Sustained Benefit in IDH1-Mutated AML
New long-term data highlights the effectiveness and safety of ivosidenib plus azacitidine for treating IDH1-mutated acute myeloid leukemia in vulnerable patients.